Phase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patients
Can't see this email? View it online
   
  July 11, 2017  
  Celiac Disease  
  The latest celiac disease news from News Medical  
 Phase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patientsPhase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patients
 
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
 
 
 Infections during infancy linked to greater risk for celiac diseaseInfections during infancy linked to greater risk for celiac disease
 
Infections during infancy are associated with increased risk for gluten intolerance (celiac disease) later on. Apparently the risk is particularly high in the case of repeated gastrointestinal infections in the first year of life.
 
   Enzyme supplement can potentially reduce uncomfortable symptoms in gluten-sensitive patientsEnzyme supplement can potentially reduce uncomfortable symptoms in gluten-sensitive patients
 
Researchers have found that taking an enzyme tablet while consuming foods containing gluten prevents a significant amount of it from entering the small intestine.
 
 Determining Permeability of Intestine Lactulose and Mannitol by Ion Chromatography with Pulsed Amperometric Detection
 
Determining Permeability of Intestine Lactulose and Mannitol by Ion Chromatography with Pulsed Amperometric DetectionThe use of ion chromatography with amperometric detection for simple and reliable determination of lactulose and mannitol in urine is described in this article.